---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-22-000026"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:31:17.480286+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q4 2021 revenue $67.3M (+95% YoY); guides 2022 revenue $260-275M

## Summary
- Q4 2021 revenue $67.3M (+95% YoY); full-year 2021 revenue $219.5M (+87% YoY).
- Net loss $10.5M in Q4 ($0.15 per share); full-year loss $75.6M ($1.11 per share).
- Test volume grew to 22,300 in Q4 (+70% YoY); full-year volume 78,565 (+77% YoY).
- 2022 revenue guidance $260M-$275M, representing 18-25% YoY growth.
- Completed acquisitions of Decipher Biosciences and HalioDx; launched Decipher Bladder test.

## SEC filing metadata
- accession: 0001384101-22-000026
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000026/0001384101-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000026/vcyt-20220228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-22-000026
- JSON: https://secwatch.observer/filing/0001384101-22-000026.json
- Plain text: https://secwatch.observer/filing/0001384101-22-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.